CU20190106A7 - Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas - Google Patents

Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas

Info

Publication number
CU20190106A7
CU20190106A7 CU2019000106A CU20190106A CU20190106A7 CU 20190106 A7 CU20190106 A7 CU 20190106A7 CU 2019000106 A CU2019000106 A CU 2019000106A CU 20190106 A CU20190106 A CU 20190106A CU 20190106 A7 CU20190106 A7 CU 20190106A7
Authority
CU
Cuba
Prior art keywords
mitoocetoscines
mitochondries
cancer cells
therapeutic agents
agents based
Prior art date
Application number
CU2019000106A
Other languages
English (en)
Inventor
Michael P Lisanti
Federica Sotgia
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of CU20190106A7 publication Critical patent/CU20190106A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/14—Libraries containing macromolecular compounds and not covered by groups C40B40/06 - C40B40/12
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Computing Systems (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Theoretical Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)

Abstract

<p>La presente descripción se refiere a compuestos que se enlazan a por lo menos una de ACAT1/2 y OXCT1/2 e inhiben la producción mitocondrial de ATP, referidos en este documento como mitocetoscinas. Se dan a conocer métodos de prospección de compuestos por la inhibición mitocondrial y propiedades anticancerosas. También se describen métodos para usar mitocetoscinas para prevenir o tratar cáncer, infecciones bacterianas y levadura patógena, así como también métodos para usar mitocetoscinas para proporcionar beneficios anti-envejecimiento. También se dan a conocer compuestos de mitocetoscina específicos.</p>
CU2019000106A 2017-06-26 2018-06-25 Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas CU20190106A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762524829P 2017-06-26 2017-06-26
PCT/US2018/039354 WO2019005698A1 (en) 2017-06-26 2018-06-25 MITOCETOSCINES: MITOCHONDRIAL THERAPEUTIC AGENTS TARGETING THE METABOLISM OF KETONES IN CANCER CELLS

Publications (1)

Publication Number Publication Date
CU20190106A7 true CU20190106A7 (es) 2020-11-30

Family

ID=64742979

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000106A CU20190106A7 (es) 2017-06-26 2018-06-25 Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas

Country Status (21)

Country Link
US (2) US11667639B2 (es)
EP (1) EP3644988B1 (es)
JP (1) JP7397672B2 (es)
KR (2) KR102646172B1 (es)
CN (1) CN110913854B (es)
AU (2) AU2018292283B2 (es)
CA (1) CA3064452A1 (es)
CL (1) CL2019003708A1 (es)
CO (1) CO2019014259A2 (es)
CR (1) CR20200033A (es)
CU (1) CU20190106A7 (es)
DO (2) DOP2019000312A (es)
EC (1) ECSP20001729A (es)
IL (2) IL292109B2 (es)
MX (1) MX2019014806A (es)
PE (2) PE20242070A1 (es)
PH (1) PH12019502892A1 (es)
RU (1) RU2020102908A (es)
SG (1) SG11201913134UA (es)
WO (1) WO2019005698A1 (es)
ZA (2) ZA201907831B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20190106A7 (es) * 2017-06-26 2020-11-30 Lunella Biotech Inc Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
CA3078791A1 (en) 2017-10-11 2019-04-18 Lunella Biotech, Inc. Anti-mitochondrial inhibitors for oncogenic ras and myc
EP3710426A4 (en) * 2017-11-03 2021-03-24 Bioimics AB ANTI-INFECTIOUS HETEROCYCLIC COMPOUNDS AND THEIR USES
EP3810284A4 (en) 2018-06-01 2022-06-15 Lunella Biotech, Inc. BIOMARKERS AND THERAPEUTICS IN RESISTANCE TO ENDOCRINE THERAPY
CU24717B1 (es) 2018-10-02 2024-08-15 Lunella Biotech Inc Derivados de azitromicina y roxitromicina como fármacos senolíticos
WO2020242857A1 (en) 2019-05-24 2020-12-03 Lunella Biotech, Inc. Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
EP0310361A3 (en) 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
SI9011409A (en) 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
FR2674522B1 (fr) 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
EP0656422B1 (en) 1993-11-05 2000-04-26 Amersham Pharmacia Biotech UK Limited Chloramphenicol acetyl transferase (CAT) assay
WO1995015770A1 (en) 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US5441939A (en) 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
CA2189001A1 (en) 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
WO1996034852A1 (en) 1995-05-03 1996-11-07 Pfizer, Inc. Novel tetracycline derivatives
CN1318434C (zh) 1997-11-25 2007-05-30 安迪珀蒂恩生物工艺学有限公司 线粒体靶向的抗氧剂
DE69919769T2 (de) 1998-03-03 2005-01-27 Pfizer Products Inc., Groton 3,6-Ketal-Makrolidantibiotika
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US7485298B2 (en) 2002-05-23 2009-02-03 Michael Powell Diagnosis and treatment of human dormancy-related sequellae
US7601332B2 (en) 2003-01-27 2009-10-13 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
TWI324600B (en) 2003-07-07 2010-05-11 Kowa Co 2,4-bis (trifluoroethoxy) pyridine compound and drug containing the compound
WO2005062851A2 (en) * 2003-12-22 2005-07-14 Pappolla Miguel A Indole-3-propionamide and derivatives thereof
EP1720555A1 (en) 2004-02-26 2006-11-15 Advanced Ocular Systems Limited Tetracycline derivatives for the treatment of ocular pathologies
US20060083727A1 (en) 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
EP1836212B1 (en) 2005-01-14 2011-09-07 Glaxo Group Limited Macrolide compounds containing biotin and photo-affinity group for macrolide target identification
EP1906948A4 (en) 2005-07-18 2010-03-17 Bipar Sciences Inc TREATMENT OF CANCER
US20080045589A1 (en) 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
JP2009539769A (ja) 2006-06-02 2009-11-19 アリアド ジーン セラピューティクス インコーポレイテッド カペシタビン併用療法
US20070292906A1 (en) 2006-06-14 2007-12-20 Bristol-Myers Squibb Company Assay for measuring acyltransferase activity
MX2009004748A (es) 2006-10-30 2009-08-25 Southern Res Inst Interaccion orientada nbs1-atm para sensibilizar celulas cancerosas a radioterapia y quimioterapia.
US9675578B2 (en) 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
US8075902B2 (en) 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
US8647673B2 (en) 2007-07-24 2014-02-11 Wayne State University Nanoparticles for imaging and treating chlamydial infection
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
EP2188630A4 (en) 2007-10-02 2010-11-03 Univ Rochester METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC ANSWERS TO ONCOGENIC MUTATIONS
WO2010121177A2 (en) 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
JP2012527231A (ja) 2009-05-20 2012-11-08 ユニヴァーシテ ド ジュネーヴ 癌開始細胞のミトコンドリア活性阻害剤及びその使用
CA2782527C (en) 2009-12-04 2019-09-17 Oncoimmune Inc. Uses of hypoxia-inducible factor inhibitors
WO2011140047A1 (en) 2010-05-04 2011-11-10 Trustees Of Dartmouth College Methods for identifying allosteric and other novel acyl-coenzyme a:cholesterol acyltransferase inhibitors
WO2012024612A1 (en) * 2010-08-20 2012-02-23 Pangea Biosciences, Inc. Cancer diagnostic and cancer therapeutic
US20120141467A1 (en) 2010-12-03 2012-06-07 Schneider Daniel J Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma
US20130172430A1 (en) 2010-12-10 2013-07-04 Michael P. Lisanti Prognosis and treatment of breast cancer
EP2723452A2 (en) 2011-06-22 2014-04-30 Vyome Biosciences Pvt Ltd Conjugate-based antifungal and antibacterial prodrugs
EP2729146B1 (en) 2011-07-08 2017-03-08 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
US9801922B2 (en) 2011-08-03 2017-10-31 University Of Iowa Research Foundation Compositions and methods of treating cancer
US9180134B2 (en) 2011-08-18 2015-11-10 Ecole Polytechnique Federale De Lausanne (Epel) Mitochondrial ribosomal proteins as aging regulators
SG11201400456RA (en) * 2011-09-09 2014-04-28 Univ New York Amido compounds as ror?tmodulators and uses thereof
WO2013040206A1 (en) 2011-09-14 2013-03-21 Lewis Thomas J Novel formulations comprising macrolide and tetracycline and their uses
CA2866080C (en) 2012-03-01 2021-01-19 University Of Cincinnati Ros-activated compounds as selective anti-cancer therapeutics
US9526795B2 (en) 2012-08-28 2016-12-27 Annam Biosciences, Llc N-BOC-dendrimers and their conjugates
US20150224169A1 (en) 2012-09-06 2015-08-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
US20140106004A1 (en) 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US9636329B2 (en) 2012-11-06 2017-05-02 Northwestern University Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
US9937161B2 (en) 2013-03-06 2018-04-10 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
US8728546B1 (en) * 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
JP2016523926A (ja) 2013-07-01 2016-08-12 ユニバーシティ オブ ジョージア リサーチ ファンデーション，インコーポレーテッド 抗癌療法のための細胞ミトコンドリアへの治療剤の正確な送達
CA2843943A1 (en) 2014-02-20 2014-05-28 Pankaj Modi Oral formulations of chemotherapeutic agents
WO2015191668A1 (en) 2014-06-10 2015-12-17 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
EP3206674B1 (en) 2014-10-17 2020-03-18 Targeted Therapies Research and Consulting Centre Multi-ingredient pharmaceutical composition for use in cancer therapy
JP6439931B2 (ja) 2015-02-26 2018-12-19 大日本印刷株式会社 吸着搬送装置および吸着搬送方法
CA2997671A1 (en) 2015-10-06 2017-04-13 Redhill Biopharma Ltd. Combination therapies for treating cancer
CN118085109A (zh) 2016-08-11 2024-05-28 昆士兰医学研究所理事会 免疫调节化合物
US20190365830A1 (en) 2017-01-18 2019-12-05 Evelo Biosciences, Inc. Methods of treating cancer
EP3570856A2 (en) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Methods of treating cancer
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
WO2018202910A1 (en) 2017-05-05 2018-11-08 Fondazione Istituto Italiano Di Tecnologia Combination of antibiotic and bcl-2 inhibitor and uses thereof
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
WO2018218242A1 (en) 2017-05-26 2018-11-29 Epicentrx, Inc. Methods and compositions for combination therapy
CU20190106A7 (es) * 2017-06-26 2020-11-30 Lunella Biotech Inc Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas

Also Published As

Publication number Publication date
RU2020102908A (ru) 2021-07-27
PE20242070A1 (es) 2024-10-18
CA3064452A1 (en) 2019-01-03
ECSP20001729A (es) 2020-02-28
CN110913854A (zh) 2020-03-24
CL2019003708A1 (es) 2020-05-15
IL292109A (en) 2022-06-01
RU2020102908A3 (es) 2021-11-15
AU2018292283A1 (en) 2019-12-12
DOP2022000142A (es) 2022-09-30
EP3644988A4 (en) 2021-03-03
AU2020257159A1 (en) 2020-11-19
IL270774A (en) 2020-01-30
JP2020525009A (ja) 2020-08-27
PH12019502892A1 (en) 2020-12-07
KR102854338B1 (ko) 2025-09-03
KR20200018814A (ko) 2020-02-20
AU2018292283B2 (en) 2020-07-23
AU2020257159B2 (en) 2022-07-14
US20200148688A1 (en) 2020-05-14
JP7397672B2 (ja) 2023-12-13
CR20200033A (es) 2020-03-05
PE20200295A1 (es) 2020-02-05
ZA202101954B (en) 2022-09-28
MX2019014806A (es) 2020-02-10
CN110913854B (zh) 2023-04-28
SG11201913134UA (en) 2020-01-30
EP3644988A1 (en) 2020-05-06
US20200207775A1 (en) 2020-07-02
CO2019014259A2 (es) 2020-04-01
IL292109B2 (en) 2024-02-01
US11667640B2 (en) 2023-06-06
DOP2019000312A (es) 2020-03-15
KR20240038805A (ko) 2024-03-25
ZA201907831B (en) 2022-07-27
IL292109B1 (en) 2023-10-01
BR112019026097A2 (pt) 2020-07-07
WO2019005698A1 (en) 2019-01-03
US11667639B2 (en) 2023-06-06
EP3644988B1 (en) 2023-02-22
KR102646172B1 (ko) 2024-03-13

Similar Documents

Publication Publication Date Title
DOP2022000142A (es) Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
DOP2022000164A (es) Mitorriboscinas: compuestos terapéuticos basados en mitocondrias que fijan como objetivo células cancerosas, bacterias y levaduras patógenas
MX2020009455A (es) Composiciones que comprenden cepas bacterianas.
MX2019005737A (es) Composicion farmaceutica para prevenir o tratar el cancer de cerebro que incluye polimorfocristalino de hexaoxido de tetraarsenico y metodo para preparar el mismo.
UY37145A (es) Ligandos de direccionamiento
MX2020004211A (es) Mitoflavoscinas: la fijacion como objetivo de enzimas que contienen flavina elimina celulas madre cancerosas (cscs) al inhibir la respiracion mitocondrial.
BR112016012870A8 (pt) composições e métodos para melhorar a produção de alface
MX2016009898A (es) Tratamientos para acne resistente.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
AR080722A2 (es) Metodo para regular la expresion de un blanco con una construccion de nucleotidos y para tratar un acondicion patologica
BR112018074304A2 (pt) composições de nanopartículas, kit e método para tratar um indivíduo com câncer resistente a fármacos
CL2021001246A1 (es) Moduladores de expresión irf5.
CL2017001329A1 (es) Conjunto bacteriano sinergístico destinado a movilizar el fósforo del suelo.
AR098819A1 (es) Método y composiciones para el control de insectos plaga en plantas por medio del silenciamiento de genes de la familia de la quitina sintasa y de la vitelogenina así como alternativamente por la expresión del gen de una toxina cry
UY30042A1 (es) Nuevos derivados de alquilfosfolípidos con citotoxicidad reducida y usos de los mismos.
CL2019002518A1 (es) Resistencia a la septoria en el apio.
BR112018009954A2 (pt) materiais e métodos para o tratamento de miopatias baseadas em titinas e outras titinopatias
MX2017008557A (es) Cepa de streptomyces sp, con actividad antimicrobiana contra microorganismos fitopatógenos, composición que la contiene y uso de la misma.